Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in Metastatic Colorectal Cancer

Collaboration to apply causal artificial intelligence and clinical trial data to identify factors that drive treatment response in patients with metastatic colorectal cancer CAMBRIDGE, Mass.– September 6, 2018 – GNS Healthcare (GNS), a leading precision medicine company, announced a cross-industry partnership with Amgen and the Alliance for Clinical Trials in Oncology (Alliance) that will apply causal […]

GNS Healthcare and Alliance for Clinical Trials in Oncology Present Results of Causal Modeling that Identifies Clinical and Molecular Drivers of Survival in Colorectal Cancer Patients

Results presented at ASCO 2018 Annual Meeting in Chicago show drivers at baseline allow better risk stratification at initiation of treatment CAMBRIDGE, Mass- June 4, 2018 – GNS Healthcare (GNS), a leading precision medicine company, together with the Alliance for Clinical Trials in Oncology (Alliance), announced today the presentation of a poster supporting results that the […]

Genentech oncology collaboration with GNS featured in TechEmergence

October 11, 2017 by Jon Walker Genentech, a member of the Roche Group, this summer announced their own collaboration with Cambridge, MA-based GNS Healthcare. GNS Healthcare’s mission statement is to use the latest innovations in machine learning to turn biomedical data into solutions and treatments. This collaboration’s first focus will also be on oncology, just like the IBM/Pfizer deal. Genentech […]

GNS Healthcare and Swedish Cancer Institute Launch Machine Learning Collaboration to Strengthen Delivery of Precision Medicine in Breast Cancer Care

Causal Computer Models to Accelerate Work of Swedish Cancer Institute’s Molecular Tumor Board CAMBRIDGE, Mass. and SEATTLE, Sept. 13, 2017 /PRNewswire/ — Leading precision medicine company GNS Healthcare (GNS) and the Swedish Cancer Institute (SCI) today announced a machine learning collaboration to strengthen, accelerate, and potentially expand the delivery of precision medicine in breast cancer care. GNS will employ its breakthrough causal machine learning and simulation […]

GNS Healthcare Announces Collaboration to Power Cancer Drug Development with REFS™ Causal Machine Learning and Simulation AI Platform

CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancer therapies. The GNS technology turns large and diverse […]

GNS Healthcare Secures $10M Series C Financing to Accelerate Development of New, Data-Driven Solutions at the Intersection of Precision Medicine and Population Health

New Investors Celgene Corporation, Alexandria Real Estate Equities, and Gi Global Health Fund LP Join Cambia Health Solutions, Heritage Provider Network, Mitsui CAMBRIDGE, Mass. – Dec. 8, 2015 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to match health interventions to individual patients and discover new target intervention pathways, […]